AGS67E

a CD37-targeting conjugate of monomethyl auristatin E and a monoclonal antibody

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 07/01/2015 - "Taken together, this study shows not only that AGS67E may serve as a potential therapeutic for B/T-cell malignancies, but it also demonstrates, for the first time, that CD37 is well expressed and a potential drug target in AML." 07/01/2015 - "We developed AGS67E, an antibody-drug conjugate that targets CD37 for the potential treatment of B/T-cell malignancies. " 07/01/2015 - "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML."
2.	T-Cell Lymphoma (Lymphoma, T Cell) 07/01/2015 - "AGS67E bound to >80% of NHL and T-cell lymphomas, 100% of CLL and 100% of AML patient-derived samples, including CD34(+)CD38(-) leukemic stem cells. "
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 07/01/2015 - "AGS67E induces potent cytotoxicity, apoptosis, and cell-cycle alterations in many non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cell lines and patient-derived samples in vitro. "
4.	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/01/2015 - "AGS67E induces potent cytotoxicity, apoptosis, and cell-cycle alterations in many non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cell lines and patient-derived samples in vitro. "

1.	Immunoconjugates (Immunoconjugate)
2.	monomethyl auristatin E